... U.S. regulators said they wouldn't review Acorda's application to sell Inbrija because of questions about the Ardsley, New York-based company's manufacturing. On the call, Cohen said the company plans to resubmit a new drug application for Inbrija ...
http://ift.tt/2zEdiMt
No comments:
Post a Comment